VitaNova Life Sciences Reports 210% Revenue Growth but Increased Net Loss in Latest Quarter

VitaNova Life Sciences Corporation reported significant financial developments in its latest 10-Q filing for the quarter ending July 31, 2026. The company generated revenues of $321,576, a substantial increase of 210% compared to $103,899 in the same period last year. This growth is attributed primarily to the introduction of a new line of healthy food products, which accounted for $234,576 of the total revenue. However, the company also reported a net loss of $123,101, worsening from a loss of $46,301 in the prior year, reflecting increased costs associated with the new product line and higher operating expenses.

The cost of revenue surged to $291,055, up 729% from $35,118 in the previous year, primarily due to the expansion of the healthy food product line. The gross profit margin fell sharply to 9% from 66% a year earlier, as the new food products typically carry lower margins. Operating expenses also rose significantly, totaling $152,683, compared to $101,221 in the prior year, driven by increased legal and professional fees. The company’s total current assets decreased to $2,223,297 from $2,430,523, while current liabilities dropped to $311,656 from $395,781, indicating improved liquidity.

In terms of strategic developments, VitaNova Life Sciences has been active in expanding its operational footprint. The company established three wholly-owned subsidiaries in 2023 and 2026, aimed at marketing and supplying dietary supplements and healthy food products. These subsidiaries include Nutripeak Trading Corporation, VitaNova Global Foods Corporation, and World Q Corporation. The company also underwent a name change from Yijia Group Corp. to VitaNova Life Sciences Corporation in January 2026, along with a 1-for-3 reverse stock split of its common stock.

Operationally, the company reported a decrease in accounts receivable, which fell to $316,871 from $726,743, and an increase in inventories, which rose to $301,294 from $105,613. The company’s cash position improved slightly, ending the quarter with $1,604,182 compared to $1,597,217 at the end of the previous quarter. Despite the challenges, management believes that current cash flows will be sufficient to meet working capital needs for the next 12 months, although they may seek additional financing if necessary.

Looking ahead, VitaNova Life Sciences aims to leverage its new product lines to drive future growth, although management cautions that the financial results for the current quarter may not be indicative of future performance. The company continues to monitor market conditions and operational efficiencies as it navigates the challenges of expanding its product offerings while managing costs.